[Source: Research & Innovation] There is overwhelming evidence that diverse teams deliver stronger and more sustainable results in science and business. To harvest the benefits of diversity, the HBP is promoting innovative leadership and invites you to its first conference on this topic in March 2018.
The conference will focus on the issue of gender balance at all career levels in the HBP, and gender and diversity considerations in research content. It will present the results and recommendations of the HBP gender equality studies and will bring in renowned experts from science and industry to equip the participants with concepts and practical tools.
By using a variety of interactive methods, the conference will also provide a space for exchanging experiences and networking.
The conference is addressed to senior scientists and young researchers as well as to project managers and members of governing bodies from within and outside the HBP.
The Art of the Biotech Deal at BIO CEO & Investor Conference

Professionals from all areas of biotechnology convened for the 20th annual BIO CEO & Investor Conference held at New York’s Marriott Marquis February 12th and 13th. Looking for deals, partnerships and collaborations, attendees participated in BIO One-on-One Partnering™, networked, listened and learned during a busy two days.
As one of the largest investor conferences focused on established and emerging publicly-traded and select private biotech companies, the event drew an enthusiastic group ready to make deals and find the right partners to move innovation to the marketplace. The key relationship-building was reflected in the 2,700 individual meetings that took place during the conference, scheduled through the partnering system.
We talked with several attendees to get their take on the conference
Things were very busy at BIO’s buzz center where interviews with thought-leaders focused on breakthrough technologies and the investment climate for biotechnology.
There was no shortage of twitter activity underscoring the impact of this event.
The market is up. Could it be thanks to #BIOCEO18 also being in NYC
– Rob Wright (@RfwrightLSL) February 12, 2018
Got to chit chat with biotech veteran Deborah Dunsire at #BIOCEO18 this a.m. Her take on the current biotech investment outlook: “It’s not the boom of 2013, but it’s not the nuclear winter of 2009 either.”
– Jessica Merrill (@Jessicaemerrill) February 13, 2018
Not a whole lot of new opioid pain meds in development (16), yet 109 non-opioids in development. Speaker says that’s still not enough as approvals of new pain meds is less than 2% #BIOCEO18 pic.twitter.com/30NXeE54ac
– Rob Wright (@RfwrightLSL) February 13, 2018
.@barbara_ryan12: “This will probably be a record year in terms of M&A and consolidation.” @sciam #BIOCEO18 Summit on #biotech and #Cancer. pic.twitter.com/uZgDXqldcB
– Michael Heinley (@mheinley) February 13, 2018
Middle ground -platform vs product companies – but platform brings critically important innovations – we can’t underestimate it. @IAmBiotech #BIOCEO18
– Donna LaVoie (@dlavoie02) February 12, 2018
#BIOCEO18 key takeaway from M&A/IPO session seems to be expectation that deals will shift back to targeting product companies rather than platform companies (as valuation is becoming too high for highly unpredictably cash flows of platform companies)$IBB $BIB $XBI
– Jack Allen (@datamonitor_JA) February 12, 2018
Great day at #BIOCEO18 @MichaelSierra16 @LEOscitech with other thought leaders discussing the crossroads of technology and #dermatology in the “Advances in Dermatology” panel pic.twitter.com/YSZa8YVMxf
– leo-scitech (@LEOscitech) February 12, 2018
Current IPO market – 2x deals in 2018 vs 2017 post JPM18 @IAmBiotech #BIOCEO18
– Donna LaVoie (@dlavoie02) February 12, 2018
“Our mission is supporting national advocacy, science and research while supporting the actionable results of promoting women in science” –@AWISNational
13 FebNabriva Therapeutics (NBRV) & Prana Biotechnology (NASDAQ:PRAN) Head to Head Review
Nabriva Therapeutics (NASDAQ: NBRV) and Prana Biotechnology (NASDAQ:PRAN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, …
Stop Measuring These Vanity Metrics in Your Marketing Campaign
There is without a doubt no shortage of data for each action you take in your marketing campaigns, nor is there a lack of tools to help you measure them. The problem is, some metrics aren’t as important as they look.
They stick out right in front of your face as soon as you log into your analytics tool, puking an “up-and-to-the-right” graph in your face.
What Are Vanity Metrics?
Vanity metrics include data such as social media followers, page views, subscribers, and other flashy analytics that are satisfying on paper, but don’t move the needle for your business goals. They offer positive reporting, but no context for future marketing decisions — something actionable metrics can do.
Beware of vanity metrics. Instead of getting caught up in the low-hanging fruit, ask yourself: “What does this graph mean? Should I continue doing something, increase the time or money I spend on a certain channel, or even stop doing something altogether?”
The obvious metrics won’t tell you this — you’ve got to dig deeper. Here are five vanity metrics you should stop obsessing over and the actionable metrics you should track instead.
1. Facebook Fans
Did you know engagement rates for branded Facebook Pages have declined by more than 20% since last year? The more that companies post content on Facebook, the more newsfeeds need to share their space, and the less users see and consume from any one company.
So, regardless of how many people have clicked “Like” once they’re on your brand’s Page, the vast majority of them never return to the Page itself and never see the content in their newsfeeds.
An Actionable Metric: Engagement Rate
Instead, use Facebook Insights, Facebook’s free analytics tool, to check which posts generate the highest level of engagement — this includes comments and shares of specific posts. The higher the level of engagement, the higher your EdgeRank score (EdgeRank is kind of like SEO for Facebook newsfeeds).
Think about the content and conversations that have the highest engagement and impressions, and come up with a plan for how you can replicate these higher-performing posts.
2. Twitter Followers
On Twitter, it really shouldn’t be about the number of followers you have. People typically follow random accounts for reasons unrelated to their actual interest in them. Many users, for example, follow you because they want you to follow them in return — and if you don’t, you often lose that follow days later.
Here are a couple of things to consider about your Twitter followers:
- Who is engaging? Add a “+” to the end of any bit.ly link or check our free tool, WhoTweetedMe.com, to see who retweets your content and identify influential followers.
- What do your followers talk about? Use Cadmus to check out their most shared links.
An Actionable Metric: Competitor Followers
With FollowerWonk, you can compare your Twitter followers to those of your competitors. If there are people following them who aren’t following you, those are prospects you aren’t connecting with, and possibly even money left on the floor.
See what types of content these competitor followers engage with to see if there are important conversations happening in your industry that you should take part in. You might even reach out to these followers and demonstrate the value of following you, too.
3. Blog Post Page Views
This indicates you’ve established yourself as a thought leader and have created great content — both good first steps in an inbound marketing plan. But page views don’t indicate where these views are coming from, if they answer a reader’s questions, or even how long he or she spent on that page.
Actionable Metrics: Bounce Rate, Social Shares
Bounce rate is the percentage of people who visit one page on your website and leave without clicking further into the site. In other words: high bounce rate = bad. Keep readers’ attention with a good call-to-action (CTA), as well as links to other content and other parts of your site. A declining bounce rate is a great metric to report because it suggests your blog is growing in its interest to your visitors.
Consider social shares, as well. Why? Search is social. Search engines like Bing and Google now consider tweets and Facebook shares in their algorithms. How many individual page viewers are also sharing your content on their social networks is a more accurate signal of long-term SEO benefits from a popular blog post.
4. Email Open Rate
Your open rate is:
Open rate is a reasonable metric to track to check the effectiveness of your email‘s subject line and timing. However, there are technical limitations because many email clients have to load images to count as an open, and many users have images turned off by default. Track this, but don’t obsess.
An Actionable Metric: Click-Through Rate
Focus on one CTA in your email that draws users to your site, and measure your click-throughs on those links. A high click-through rate (CTR) for an email that invites users to download something on your website, for example, tells you the email campaign has high lead-generating power.
5. Number of Subscribers/Product Users
It’s simple enough to track how many people have converted into a trial user, or agreed to receive your newsletter. But are people actually consuming your product and content? Often this product demo or email goes unused or unseen.
Actionable Metrics: Active Users, Path to Conversion
Instead, track how many users return to use your product each day. These are called active users. In Google Analytics, metrics like visitor loyalty and visitor recency are helpful, depending on your product. As for ecommerce, measure repeat customers and retention. Zappos, which sees more than $2 billion in revenue, gets 75% of its sales from repeat customers.
In addition, track which content drew in leads that converted to qualified contacts or even customers — as well as what actions those leads took on your website before they converted. You can monitor this information a few ways, such as adding tracking links to your CTAs so you can see where a user came from as they moved through the conversion path. Rinse, lather, repeat.
Of course, don’t just throw all of these vanity metrics out at once. Before you add or erase certain data from your marketing analytics reports, make sure you and your team have defined your goals and the data points you’ll use to measure whether or not you’re achieving them.
Vertex Pharma Gets FDA Approval for Combo CF Drug, Sets $292,000 Price

The FDA has approved a new Vertex Pharmaceuticals cystic fibrosis drug, clearing the way for the Boston company to bring to the market its third treatment for the inherited disorder.
The new Vertex (NASDAQ: VRTX) drug pairs the already approved ivacaftor (Kalydeco) with the newly approved drug tezacaftor. Vertex set a list price for its ivacaftor/tezacaftor (Symdeko) combination at $292,000 per year.
Cystic fibrosis (CF) is a genetic disorder that causes a thick buildup of mucus in the lungs and pancreas. The approval of ivacaftor/tezacaftor strengthens Vertex’s case that drug combinations are the right approach to treating the disease. The… Read more »
UNDERWRITERS AND PARTNERS
CRISPR Therapeutics’ Lundberg Steps Down as Chief Scientific Officer
Bill Lundberg is leaving his position as chief scientific officer of CRISPR Therapeutics (NASDAQ: CRSP). CRISPR Therapeutics, which has operations in Switzerland and Cambridge, MA, said that Lundberg will continue as an advisor to the company and he is now head of its scientific advisory board. CRISPR Therapeutics develops treatments based on the CRISPR-Cas9 gene editing system. The company is preparing to start a clinical trial testing a treatment for the rare blood disease beta-thalassemia, part of a multi-drug partnership with Boston-based Vertex Pharmaceuticals (NASDAQ: VRTX).
UNDERWRITERS AND PARTNERS
Research Headlines – Targeting leukaemia with personalised treatment
[Source: Research & Innovation]
EU-funded researchers are developing a personalised dosing solution for chemotherapy targeting leukaemia using advanced microfluidic chips to meet the precise medical requirements of individual patients.
#BIOCEO18: Paradigm Shift Creating New Opportunities in China

The past few years have been a time of tremendous change in the world’s second largest market for biopharmaceuticals: China. What these changes mean for biopharmaceutical companies looking to break into the market – or find a new potential source of investment capital – was the subject of a lively panel at the opening day of the 2018 BIO CEO and Investor Conference in New York.
Moderated by BIO Executive Vice President for International Affairs Joseph Damond, the panelists included:
- Alex Jung, Managing Director, Parthenon-EY, Ernst & Young LLP
- Michael Keyoung, MD, PhD, Managing Director and Head of North America, C-Bridge Capital
- Yuwen Liu, Founding Partner, BOHE Angel Fund; former Chairwoman & CEO, Suzhou Industrial Park Biotech Development Co. Ltd. (BioBAY)
- Hummer Mars, Executive Director, China Group, Global Investment Banking Division, NYIC
- Kimberly Nearing, Managing Director, Head of Life Sciences, Cedrus Group
- Dan Zhang, MD, Chairman, Fountain Medical Development
BIO’s Damond summed up the shift in his opening remarks:
“One of the things we’ve been following a lot in the past couple of years is the fact that China has been doing a lot to reform its regulatory and drug approval regime from one that is under-resourced and lagged tremendously from approval dates in the US and Europe to one that is better resourced and more aligned with regulatory practices in the developed world. And this is part of China’s goal of developing the right conditions to do drug development in China.”
As Kimberly Nearing of the Cedrus Group noted, “Western companies that are sitting on the sidelines to see what’s going to happen in China, this might be the impetus to start including China in their plans. We hear from a lot of clients, and rightly so, that the value of their assets to potential partners in China just increased because of the reduction in development time.”
C-Bridge Capital’s Michael Keyoung observed that the changes have meant a shift from focusing on me-too products to true innovation. “If you’ve followed China in the last 5 years, there’s a big dynamic shift in the past 2 years… if you’re a VC investor you invested in a different type of Chinese biotech company these past 3-4 years,” said Keyoung. “You were focused on fast followers and a different type of drug development. Now with the change of regulation, you really have to focus on innovation.”
The panelists had a few pieces of advice for those looking to break into the Chinese market. First, do your homework. Ms. Nearing stressed the importance of thorough due diligence with any potential partner, and spelling out in lengthy and explicit detail the division of labor and decision-making structure for partnerships.
Several panelists also advised finding the right strategic advisor who can guide through the complex Chinese landscape, where a clear understanding of the regulatory and investment landscape is paramount for success.
Read more coverage of the 2018 BIO CEO & Investor Conference.
Better Health and care, economic growth and sustainable health systems
[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: H2020-SC1-BHC-2018-2020Pillar: Societal ChallengesPlanned Opening Date: Deadline: Tue, 2 Oct 2018 17:00:00 (Brussels local time)Modification Date: Sun, 11 Feb 2018Latest information: The submission of proposals to topic SC1-BHC-15-2018 (first stage – outline proposals) closed on 06 February 2018. A total of 30 proposals were submitted.
SME Instrument
[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: H2020-EIC-SMEInst-2018-2020Pillar: Industrial LeadershipOpening Date: Deadline: Wed, 5 Sep 2018 17:00:00 (Brussels local time)Modification Date: Sat, 10 Feb 2018Latest information: A total number of 2,009 proposals were submitted in response to the SME-1 (Phase I) February, 8th 2018 cut-off (H2020-EIC-SMEINST-1-2018_08-02-2018).





